Replies to post #107474 on Biotech Values

[DewDiligence]

VRUS—would a partnership for any of its HCV nukes propel the stock materially higher from the current market cap?

Actually, the only nuke that VRUS is seeking to partner is PSI-7977 (the pyrimidine). VRUS intends to keep PSI-938 (the purine) in-house in order to develop a combination pill consisting of the two nukes.

[genisi]

VRUS/more upside - perhaps when final data from RG7128 PROPEL study (AASLD abs of interim) and PSI-7977 phase IIb are out.